Access type

Forgot your password? Click here

DMP_ForgotOK Close


If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.


Eugenio Aringhieri

Chief Executive Officer

Eugenio Aringhieri is CEO of the Dompé Group, an Italian biopharmaceutical company.

Since 2007, in line with the wishes of its Shareholder, he has promoted the company’s functional reorganisation and given impetus to its industrial strategy with the aim of making the Group an internationally recognised science-based company.

To this end, in 2008 he consolidated its partnership with Amgen by creating Amgen Dompé, an equal joint venture of which he was President, and established the strategic programme and priority objectives of Biogen Dompé, an equal joint venture - of which he was CEO - between Biogen Idec, the world’s leading biotech company, and Dompé, thus consolidating their initial marketing agreement into a partnership by creating a new company in Italy and Switzerland.

With a focus on the value of innovation in research into biotechnological therapeutic solutions to global health problems, Aringhieri promotes an international approach based on the network.

He was Vice-President of the Board of Directors of Philogen, an outstanding Italo-Swiss biotech company dedicated to developing products for the treatment of cancer, rheumatoid arthritis and certain eye diseases, of which Dompé is the majority shareholder.

He joined the Board of Directors of AAA (Advanced Accelerator Applications), a leading company in the field of molecular medicine. In the same year, he became President and Managing Director of Anabasis, an Italian biotech company that develops innovative drugs based on rhNGF (the discovery of which led to Prof. Rita Levi Montalcini being awarded the Nobel Prize) for the treatment of serious eye diseases for which no effective therapy is currently available, whose acquisition was completed in February 2012.

Aringhieri has also actively supported high-tech startups and since 2016 he has been a Member of the e-Novia Board of Directors, a company focused on fostering business innovation through international research projects and partnershaips.

In 2015, Aringhieri was named “Best CEO in Therapeutics Innovations Industry” at the European CEO Awards, one of the most renowned professional awards for CEOs.

In May 2016 Aringhieri was awarded with “Best European CEO” prize in Biotech, by “CEO Insight” Magazine, and featured in “Acquisition International” Magazine as one of the most influential CEOs in Life Sciences Sector.

Watch Eugenio Aringhieri's interview for European CEO

Institutional appointments

  • In 2016, he was re-elected President of Farmindustria’s Biotech Group for a third consecutive mandate.
  • Since 2016, he has been a Council Member of the Cluster Nazionale Scienza della vita Alisei.
  • Since 2015, he has been a Member of the Steering Committee of the CRUI Foundation’s University-Business Observatory.
  • Since 2014, he has been Farmindustria's representative on the National Committee for Biosafety, Biotechnologies and Life Sciences, established by the Presidency of the Council of Ministers.
  • Since 2008, he has been a Member of the International Board of European Biopharmaceutical Enterprises (EBE).
  • Since 2000, he has been a Member of the Board of Governors of Farmindustria.